

Chemoselective Dehydrogenation of 3-[2-(3,4-Dihydro-1-naphthalenyl)ethyl]imidazolidine-2,4-diones: a New and Convenient Synthesis of 13,16-Diazaequilenin analogs

PARIHAR, J. A. RAMANA, M. M. V*

Department of Chemistry, University of Mumbai, Santacruz (E), Mumbai-400098, India

The synthesis of the title compounds starting with the chemoselective dehydrogenation of 3-[2-(3,4-dihydro-1-naphthalenyl)ethyl]imidazolidine-2,4-diones has been described.


Keywords chemoselective dehydrogenation, imide reduction, intramolecular cyclization, 13,16-diazaasteroid

Azasteroids are known to exhibit varied biological properties which include analgesic,¹ antiandrogenic,² antiphlogistic,³ antimicrobial,⁴ antileukemia,⁵ antifungal,⁶ bactericidal,⁷ antiestrogenic,⁸ antifertility,⁹ and cardiotoxic and hypotensive activity.¹⁰ Moreover some of the azasteroids act as neuromuscular blockers¹¹ such as 5- α reductase inhibitors or androgen receptors.¹² Though several syntheses of azasteroids¹³⁻¹⁸ have been reported, the title compounds have not yet been synthesized. Recently we have reported the first synthesis of 13,16-diazaestrone analogs.¹⁹ In this article we wish to report the first synthesis of 13,16-diazaequilenin analogs.

Towards this end, chemoselective dehydrogenation of

3-[2-(3,4-dihydro-1-naphthalenyl)ethyl]imidazolidine-2,4-diones **1a—1c** which was the key step was explored for the synthesis of **2a—2c**. We heated **1a—1c** with 5% Pd-C at 250 °C for 15 min and to our delight the corresponding dehydrogenated products **2a—2c** were obtained in 67%—70% yield. It is noteworthy that only carbocyclic ring was chemoselectively dehydrogenated to afford **2a—2c**. Prolonging the reaction time decreased considerably the yield as well as the purity of the product. The structures of **2a—2c** were ascertained by their elemental analysis and spectroscopic data. The ¹H NMR spectrum of **2a** displayed 2H singlet at δ 3.93 for H-5 of the imidazolidine ring and 1H broad singlet at δ 5.39 for N—H apart from two triplets in the

Scheme 1 Synthesis of 13,16-diazaequilenin analogs



Reagents and conditions: i) 5% Pd-C, 250 °C, 15 min. ii) Method-A: NaBH₄, dry MeOH, reflux, 6 h; Method-B: LiAlH₄, dry THF, r.t., 30 h; Method-C: DIBAL-H (20% toluene solution), dry THF, -78 °C, 2 h. iii) PPA, steam bath, 6 h.

* E-mail: mmvramana@indiatimes.com

Received November 24, 2003; revised January 4, 2004; accepted May 25, 2004.

Table 1 Synthesis of 13,16-diazaequilenin analogs

| Compound | R ¹ | R ² | Physical appearance, m.p. ^a /°C | Yield ^b /% |
|-----------|-----------------|----------------|--|---|
| 2a | H | H | colourless solid, 127—129 | 69 |
| 2b | CH ₃ | H | colourless solid, 98 | 70 |
| 2c | H | Cl | colourless oil | 67 |
| 3a | H | H | pale yellow oil | 49 ^c (25), ^d 71, ^e 69 ^f |
| 3b | CH ₃ | H | colourless solid, 128—129 | 43 ^c (27), ^d 64, ^e 72 ^f |
| 3c | H | Cl | pale yellow oil | 41 ^c (26), ^d 70, ^e 77 ^f |
| 4a | H | H | colourless solid, 221 | 70 |
| 4b | CH ₃ | H | colourless solid, 210—211 | 69 |
| 4c | H | Cl | colourless solid, 184—186 | 41 |

^a Melting points are un-corrected. ^b Yield refers to purified product. ^c Yield obtained from method-A. ^d % of starting material recovered in method-A. ^e Yield obtained from method-B. ^f Yield obtained from method-C.

aliphatic region, thus confirming the chemoselective dehydrogenation at only carbocyclic ring.

Chemoselective reduction of NCOCH₂ group of **2a—2c** was carried out with NaBH₄ in MeOH under reflux for 6 h to give the corresponding hydroxy lactam **3a—3c** in 41%—49% yield along with the recovery of the starting material (25%—27%). Prolonging the reaction time (up to 12 h) and using more equivalents of NaBH₄ (3 equiv.) did not improve the yield of the hydroxy lactam **3a—3c**. The structures of **3a—3c** were ascertained by their elemental analysis and spectroscopic data. The ¹H NMR spectrum of **3a** displayed 1H multiplet at δ 6.10—6.13 for H-4 of the imidazolidine ring, 1H broad singlet at δ 6.24 for O—H and 2H multiplet at δ 2.20—2.33 for H-5 of the imidazolidine ring, confirming the chemoselective reduction at NCOCH₂ group. Replacing NaBH₄ in MeOH with LiAlH₄ in THF for 30 h at r.t. and DIBAL-H (20% toluene solution) in THF at -78 °C for 2 h improved the yield of **3a—3c** to 64%—71% and 69%—77% respectively. Intramolecular cyclization of **3a—3c** was carried out in polyphosphoric acid (PPA) on a steam bath for 6 h to afford the corresponding 13,16-diazaequilenin analogs **4a—4c** in 41%—70% yield (Scheme 1, Table 1). The ¹H NMR spectrum of **4a** displayed 1H multiplet at δ 4.00—4.03 for H-3a, 1H multiplet at δ 4.30—4.34 for H-3a, 1H broad singlet at δ 5.66 for NH and 5H multiplet at δ 3.01—3.52, which confirms the intramolecular cyclization of **3a** to give **4a**.

In conclusion, the methods described for the synthesis of 13,16-diazasteroids **4a—4c** is short, general and utilizes easily accessible materials.

Experimental

General procedure for the synthesis of dehydrogenated products **2a—2c**

Seco-azasteroid **1** (100 mg) was heated with 5% Pd-C (50 mg) at 250 °C for 15 min. It was extracted with hot EtOAc (4×50 mL). The combined EtOAc extract was filtered to remove trace of catalyst. The

evaporation of solvent gave a brown residue which was purified by column chromatography [alumina (neutral), CHCl₃ : MeOH (97 : 3, V : V)] to afford the corresponding dehydrogenated product **2a—2c**.

3-[2-(1-Naphthalenyl)ethyl]imidazolidine-2,4-dione (2a): UV (CHCl₃) λ_{\max} (log ϵ): 272 (3.83), 283 (3.92), 292 (3.79) nm; ¹H NMR (CDCl₃, 500 MHz) δ : 3.39 (t, $J=7.9$ Hz, 2H, ArCH), 3.88 (t, $J=7.9$ Hz, 2H, NCH), 3.93 (s, 2H, H-5 of naphthalene ring), 5.39 (br, s, 1H, NH), 7.77—7.87 (m, 5H, H-3—7 of naphthalene ring), 7.86 (d, $J=8.0$ Hz, 1H, H-2 of naphthalene ring), 8.23 (d, $J=8.3$, 1H, H-8 of naphthalene ring); IR (KBr) ν : 1720 & 1781 (C=O), 3250 (N—H) cm⁻¹. Anal. calcd for C₁₅H₁₄N₂O₂: C 70.85, H 5.55, N 11.02; found C 70.78, H 5.60, N 10.97.

3-[2-(7-Methyl-1-naphthalenyl)ethyl]imidazolidine-2,4-dione (2b): UV (CHCl₃) λ_{\max} (log ϵ): 271 (3.84), 282 (3.90), 292 (3.74) nm; ¹H NMR (CDCl₃, 60 MHz) δ : 2.50 (s, 3H, CH₃), 3.33 (t, $J=8$ Hz, 2H, ArCH₂), 3.80—4.00 (m, 4H, NCH), 6.33 (br, s, 1H, NH), 7.10—8.40 (m, 6H, ArH); IR (KBr) ν : 1705 & 1782 (C=O), 3250 (N—H) cm⁻¹. Anal. calcd for C₁₆H₁₆N₂O₂: C 71.62, H 6.01, N 10.44; Found C 71.69, H 5.98, N 10.41.

3-[2-(5-Chloro-1-naphthalenyl)ethyl]imidazolidine-2,4-dione (2c): UV (CHCl₃) λ_{\max} (log ϵ): 271 (3.73), 281 (3.76), 292 (3.62) nm; ¹H NMR (CDCl₃, 60 MHz) δ : 3.25 (t, $J=8$ Hz, 2H, ArCH₂), 3.75—4.10 (m, 4H, NCH), 6.15 (br, s, 1H, NH), 7.25—8.40 (m, 6H, ArH); IR (oil film) ν : 1713 & 1780 (C=O), 3300 (N—H) cm⁻¹. Anal. calcd for C₁₅H₁₃ClN₂O₂: C 62.40, H 4.54, Cl 12.28, N 9.70; found C 62.38, H 4.59, Cl 12.33, N 9.64.

General procedure for the synthesis of hydroxy lactams **3a—3c**

Method-A: Reduction with NaBH₄ in methanol.

To a well-stirred solution of dehydrogenated compound **2** (1 mmol) in dry MeOH (50 mL) was added gradually NaBH₄ (76 mg, 2 mmol) in dry MeOH (20 mL) at r.t. and the mixture was refluxed with stirring for

6 h. After MeOH was removed the residue was quenched with 5% NH₄Cl solution (100 mL). It was extracted with CHCl₃ (3 × 25 mL). The combined CHCl₃ extracts were washed with water (2 × 25 mL) and then dried (anhydr. Na₂SO₄). The evaporation of solvent gave a brown residue which was purified by column chromatography [alumina (basic), chloroform : MeOH (98 : 2)] to furnish starting material **2a—2c**. Further elution with chloroform : MeOH (96 : 4) followed by recovery of solvents gave hydroxy lactam **3a—3c**.

1-[2-(1-Naphthalenyl)ethyl]-5-hydroxyimidazolidin-2-one (3a): UV (CHCl₃) λ_{max} (log ε): 271 (3.67), 283 (3.90), 291 (3.65) nm; ¹H NMR (CDCl₃, 200 MHz) δ: 2.20—2.33 (m, 2H, NHCH₂), 3.36 (t, *J*=7.9 Hz, 2H, ArCH₂), 3.78 (t, *J*=7.9 Hz, 2H, NCH₂), 6.10—6.13 (m, 1H, HOCHN), 6.24 (br, s, 1H, OH), 7.05—8.00 (m, 7H, ArH), 8.76 (br s, 1H, NH); IR (oil film) ν: 1675 (C=O), 3200—3500 (N—H and O—H) cm⁻¹. Anal. calcd for C₁₅H₁₆N₂O₂: C 70.29, H 6.29, N 10.93; found C 70.41, H 6.23, N 10.97.

1-[2-(7-Methyl-1-naphthalenyl)ethyl]-5-hydroxyimidazolidin-2-one (3b): UV (CHCl₃) λ_{max} (log ε): 271 (3.79), 282 (3.87), 291 (3.71) nm; ¹H NMR (CDCl₃, 200 MHz) δ: 2.18—2.30 (m, 2H, NHCH₂), 2.51 (s, 3H, CH₃), 3.40 (t, *J*=7.8 Hz, 2H, ArCH₂), 3.80 (t, *J*=7.8 Hz, 2H, NCH₂), 6.04—6.07 (m, 1H, HOCHN), 6.19 (br, s, 1H, OH), 7.20—7.89 (6H, m, ArH), 8.90 (br, s, 1H, N—H); IR (KBr) ν: 1677 (C=O), 3200—3500 (N—H and O—H) cm⁻¹. Anal. calcd for C₁₆H₁₈N₂O₂: C 71.09, H 6.71, N 10.36; found C 70.98, H 6.74, N 10.30.

1-[2-(5-Chloro-1-naphthalenyl)ethyl]-5-hydroxyimidazolidin-2-one (3c): UV (CHCl₃) λ_{max} (log ε): 271 (3.73), 282 (3.84), 292 (3.61) nm; ¹H NMR (CDCl₃, 200 MHz) δ: 2.20—2.32 (m, 2H, NHCH₂), 3.38 (t, *J*=7.8 Hz, 2H, ArCH₂), 3.80 (t, *J*=7.8 Hz, 2H, NCH₂), 6.00—6.03 (m, 1H, HOCHN), 6.24 (br, s, 1H, OH), 7.28—8.04 (m, 6H, ArH), 8.84 (br, s, 1H, N—H); IR (oil film) ν: 1680 (C=O); 3200—3500 (N—H and O—H) cm⁻¹. Anal. calcd for C₁₅H₁₅Cl N₂O₂: C 61.97, H 5.20, Cl 12.19, N 9.63; found C 61.89, H 5.24, Cl 12.24, N 9.59.

Method-B: Reduction with LiAlH₄ in THF.

To a well-stirred suspension of LiAlH₄ (38 mg, 1 mmol) in dry THF (50 mL) at r.t. was added gradually dehydrogenated compound **2** (1 mmol) in dry THF (20 mL) and the mixture was stirred at the same temperature for 30 h. THF was removed by distillation at r.t. on rota-vapour and the residue was quenched with 5% NH₄Cl solution (100 mL). For isolation and purification the same procedure as given in method-A was followed. The ¹H NMR spectral data of **3a—3c** were consistent with its authentic data obtained in method-A.

Method-C: Reduction with DIBAL-H (20% toluene solution) in THF.

To a well-stirred solution of dehydrogenated compound **2** (1 mmol) in dry THF (50 mL) was added DIBAL-H (2 mL of 20% toluene solution, 2 mmol) at -78 °C and the mixture was stirred for 2 h at the same temperature. The

reaction mixture was quenched with 5% NH₄Cl solution (100 mL). For isolation and purification the same procedure as given in method-A was followed. The ¹H NMR spectral data of **3a—3c** were consistent with its authentic data obtained in method-A.

General procedure for the synthesis of 13,16-diazasteroids **4a—4c**

A mixture of hydroxy lactam **3** (50 mg) and PPA (10 g) was heated on steam bath for 6 h. The reaction mixture was poured onto ice and allowed to stand overnight. It was extracted with EtOAc (3 × 25 mL). The combined EtOAc layer was washed with 10% Na₂CO₃ (2 × 25 mL), water (2 × 25 mL) and then dried (anhydr. Na₂SO₄). The evaporation of solvent gave a brown residue which was purified by column chromatography [alumina (basic), chloroform : MeOH (98 : 2)] to furnish the title compounds **4a—4c**.

3,3a,10,11-Tetrahydrobenzo[*f*]imidazo[5,1-*a*]isoquinolin-1[2*H*]-one (4a): UV (CHCl₃) λ_{max} (log ε): 272 (3.83), 281 (3.86), 293 (3.70) nm; ¹H NMR (CDCl₃, 200 MHz) δ: 3.01—3.52 (m, 5H, H-3, H-10 & H-11 axial), 4.00—4.03 (m, 1H, H-3a), 4.30—4.34 (m, 1H, H-11 equatorial), 5.66 (br, s, 1H, N—H), 7.18—8.10 (m, 6H, ArH); IR (KBr) ν: 1695 (C=O), 3200 (N—H) cm⁻¹. Anal. calcd for C₁₅H₁₄N₂O: C 75.61, H 5.92, N 11.76; found C 75.72, H 5.88, N 11.82.

3,3a,10,11-Tetrahydro-8-methylbenzo[*f*]imidazo[5,1-*a*]isoquinolin-1[2*H*]-one (4b): UV (CHCl₃) λ_{max} (log ε): 271 (3.77), 283 (3.92), 291 (3.68) nm; ¹H NMR (CDCl₃, 200 MHz) δ: 2.51 (s, 3H, CH₃), 3.00—3.50 (m, 5H, H-3, H-10 & H-11 axial), 4.01—4.04 (m, 1H, H-3a), 4.33—4.37 (m, 1H, H-11 equatorial), 5.07 (br, s, 1H, N—H), 7.11—8.00 (m, 5H, ArH); IR (KBr) ν: 1695 (C=O str.), 3300 (N—H str.) cm⁻¹. Anal. calcd for C₁₆H₁₆N₂O: C 76.16, H 6.39, N 11.10; found C 76.07, H 6.43, N 11.06.

6-Chloro-3,3a,10,11-Tetrahydrobenzo[*f*]imidazo[5,1-*a*]isoquinolin-1[2*H*]-one (4c): UV (CHCl₃) λ_{max} (log ε): 271 (3.68), 283 (3.77), 291 (3.60) nm; ¹H NMR (CDCl₃, 200 MHz) δ: 3.06—3.54 (m, 5H, H-3, H-10 & H-11 axial), 4.04—4.07 (m, 1H, H-3a), 4.38—4.42 (m, 1H, H-11 equatorial), 5.51 (br, s, 1H, N—H), 7.20—8.08 (m, 5H, ArH); IR (KBr) ν: 1700 (C=O), 3350 (N—H) cm⁻¹. Anal. calcd for C₁₅H₁₃ClN₂O: C 66.06, H 4.80, Cl 13.00, N 10.27; found C 65.98, H 4.82, Cl 13.04, N 10.25.

References

- 1 Taylor, E. C.; Lenard, K. *J. Chem. Soc., Chem. Commun.* **1967**, 97.
- 2 Shibata, K.; Takeguwa, S.; Koizumi, N.; Yamakoshi, N.; Shimazawa, E. *Chem. Pharm. Bull.* **1992**, *40*, 935.
- 3 Akherm, A. A.; Lakhvich, F. A.; Pshenichnyi, V. N.; Lis, L. G.; Kuzmitskii, B. B.; Mizulo, N. A. *USSR 636236*, **1978** [*Chem. Abstr.* **1979**, *90*, 104210t].
- 4 Norman, F. P.; Doorenbos, N. J. *J. Miss. Acad. Sci.* **1976**, *21*,

- 23 [*Chem. Abstr.* **1977**, 86, 165794a].
- 5 Anastasiou, A.; Catsoulacus, P.; Epitheor, K. *Farmakol Farmakokinet. Intd. Ed.* **1992**, 6, 130 [*Chem. Abstr.* **1993**, 119, 72911w].
- 6 Patrick, G. L.; Kinsman, O. S. *Eur. J. Med. Chem.* **1996**, 31, 615 [*Chem. Abstr.* **1997**, 125, 222255a].
- 7 William, R. H.; Hoehn, M. M.; Michel, K. H. *US 147808*, **1994** [*Chem. Abstr.* **1995**, 123, 75620u].
- 8 Greenbalatt, R. B.; Bornstan, R.; Bohler, C. S. S. *J. Reprod. Med.* **1974**, 13, 201.
- 9 Kierstead, R. W.; Faraone, A.; Boris, A. *J. Med. Chem.* **1969**, 12, 629.
- 10 Akherm, A. A.; Lakhvich, F. A.; Pshenichnyi; Lakhvich, O. F.; Kuzmitskii, B. B.; Gorbatenko, S. F. *USSR 636235*, **1978** [*Chem. Abstr.* **1979**, 90, 104211u].
- 11 Li, X.; Singh, S. M.; Lourdusamy, M.; Merand, Y.; Veitleux, R.; Labrie, F. *Bioorg. Med. Chem. Lett.* **1995**, 5, 1061.
- 12 Bakshi, R. K.; Patel, G. F.; Rasmussan, G. H. *US 373341*, **1995** [*Chem. Abstr.* **1995**, 123, 212693c].
- 13 Schleigh, W. R.; Catala, A.; Popp, F. D. *J. Heterocycl. Chem.* **1965**, 2, 379.
- 14 Birch, A. J.; Subba Rao, G. S. R. *J. Chem. Soc.* **1965**, 3007.
- 15 Kessar, S. V.; Singh, M.; Kumar, A. *Tetrahedron Lett.* **1965**, 3245.
- 16 Hubert, J. C.; Speckamp, W. N.; Huisman, H. O. *Tetrahedron Lett.* **1969**, 1553.
- 17 Dijkink, J.; Speckamp, W. N.; Huisman, H. O. *Tetrahedron* **1978**, 34, 173.
- 18 Trehan, I. R.; Bala, K.; Singh, J. B. *Indian J. Chem.* **1979**, 18B, 295.
- 19 Parihar, J. A.; Ramana, M. M. V. *Tetrahedron Lett.* **2003**, 44, 1843.

(E0312241 LI, W. H.)